Accor : L’annonce sur Air France KLM éclipsée par des résultats S1 et une guidance légèrement inférieure aux attentes
>La solide tendance de RevPAR devrait se poursuivre au S2 - Accor a publié de solides RevPAR au S1, en ligne avec nos attentes à +5.1%, suggérant un léger ralentissement au T2 (Amérique du Nord / Centrale, Amérique du Sud) malgré des dynamiques toujours très solides dans les principaux marchés du groupe (France/Europe à +5,9% et Asie Pacifique à +4.8%). Les perspectives restent bien orientées au S2 (soutien du segment Tourisme en France et calendrier plus favorable en...Shenzhen Accord Pharmaceutical is engaged in the research, development and production of pharmaceuticals; and wholesales and chain retails of Chinese and western patent medicine, Chinese traditional medicine, biological products, bio-chemical medicine, health care products and medical apparatus and instruments. Through its subsidiaries, Co. is also engaged in the manufacture of raw material for chemical medicine, processing of Chinese patent drugs and medical chemical raw materials; sale of antibiotic preparations, chemical reagent and Chinese medical crop; and provision of logistic and storage services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.